Methods of Calculating Prostate-Specific Antigen Velocity

European Urology

Volumn 52, Issue 4, 2007, Pages 1044-1051

  Connolly, David ^a,b   Black, Amanda ^b   Murray, Liam J ^b   Napolitano, Giulio ^b   Gavin, Anna ^b   Keane, Patrick F ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Calculation; Linear regression; Method; PSA; PSA velocity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEN'S HEALTH; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; HUMANS; MALE; MIDDLE AGED; NORTHERN IRELAND; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC DISEASES; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34548259960     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.12.017     Document Type: Article

References (22)

1. Catalona W.J., and Loeb S. The PSA era is not over for prostate cancer. Eur Urol 48 (2005) 541-545
2. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909-916
3. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
4. Smith D.S., and Catalona W.J. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 152 (1994) 1163-1167
5. Mettlin C., Murphy G.P., Lee F., et al. Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol 152 5 pt 2 (1994) 1737-1740
6. Berger A.P., Deibl M., Steiner H., et al. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate 64 (2005) 240-245
7. Fang J., Metter E.J., Landis P., et al. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 59 (2002) 889-893 discussion 893-4
8. Loeb S., Roehl K.A., Graif T., et al. PSA velocity threshold for predicting prostate cancer in young men with PSA < 4 ng/ml. J Urol 175 4 Suppl (2006) 153
9. Raaijmakers R., Wildhagen M.F., Ito K., et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 63 (2004) 316-320
10. Roobol M.J., Kranse R., de Koning H.J., et al. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (Rotterdam). Urology 63 (2004) 309-313 discussion 313-5
11. Schröder F.H., Roobol M.J., van der Kwast T.H., et al. Does PSA velocity predict prostate cancer in pre-screened populations?. Eur Urol 49 (2006) 460-465 (discussion 465)
12. Northern Ireland Statistics and Research Agency. Northern Ireland Census 2001 Key Statistics. Belfast: National Statistics; 2002. Available at: http://www.nisranew.nisra.gov.uk/census/Census2001Output/KeyStatistics/keystats.html. Accessed on 18 September 2006.
13. Gavin A., McCarron P., Middleton R.J., et al. Evidence of prostate cancer screening in a UK region. BJU Int 93 (2004) 730-734
14. Carter H.B., Pearson J.D., Waclawiw Z., et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 45 (1995) 591-596
15. Perrin P. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence. Eur Urol 49 (2006) 418-419
16. Eastham J.A., Riedel E., Scardino P.T., et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 289 (2003) 2695-2700
17. Soletormos G., Semjonow A., Sibley P.E., et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 51 (2005) 1342-1351
18. Collins G.N., Martin P.J., Wynn-Davies A., et al. The effect of digital rectal examination, flexible cystoscopy and prostatic biopsy on free and total prostate specific antigen, and the free-to-total prostate specific antigen ratio in clinical practice. J Urol 157 (1997) 1744-1747
19. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
20. D'Amico A.V., Renshaw A.A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
21. Benecchi L. PSA velocity and PSA slope. Prostate Cancer Prostatic Dis 9 (2006) 169-172
22. Svatek R.S., Shulman M., Choudhary P.K., et al. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 106 (2006) 1047-1053